Changeflow GovPing Healthcare & Life Sciences Ponesimod Patent with Teriflunomide or Leflunomide
Routine Notice Added Final

Ponesimod Patent with Teriflunomide or Leflunomide

Favicon for changeflow.com USPTO Patent Applications - Therapeutics (A61P)
Published
Detected
Email

Summary

USPTO published Application US20260108501A1 on April 23, 2026, covering a pharmaceutical combination of ponesimod with either teriflunomide or leflunomide. Inventors are Martine Clozel and Laetitia Pouzol, with filing date December 22, 2025, and application number 19429084. The combination is classified under CPC A61P 25/28, indicating neurological therapeutic applications.

“The present invention relates to a pharmaceutical combination comprising a first active ingredient which is ponesimod and a second active ingredient which is selected from the group consisting of teriflunomide and leflunomide.”

USPTO , verbatim from source
Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 219 changes logged to date.

What changed

USPTO published a new patent application for a pharmaceutical combination of ponesimod with teriflunomide or leflunomide. The application claims a combination therapy with potential neurological applications under CPC classification A61P 25/28.

Pharmaceutical companies and patent applicants monitoring the MS/treatment pipeline should review this filing for competitive landscape awareness. This publication does not grant patent rights but establishes prior art as of the filing date.

Archived snapshot

Apr 23, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

PHARMACEUTICAL COMBINATION COMPRISING PONESIMOD

Application US20260108501A1 Kind: A1 Apr 23, 2026

Inventors

Martine Clozel, Laetitia Pouzol

Abstract

The present invention relates to a pharmaceutical combination comprising a first active ingredient which is ponesimod and a second active ingredient which is selected from the group consisting of teriflunomide and leflunomide.

CPC Classifications

A61K 31/426 A61K 31/167 A61K 31/421 A61P 25/28

Filing Date

2025-12-22

Application No.

19429084

View original document →

Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 23rd, 2026
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260108501A1

Who this affects

Applies to
Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent application Pharmaceutical R&D
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!